Tipranavir
From Wikipedia, the free encyclopedia
Tipranavir
|
|
Systematic (IUPAC) name | |
N-[3-[1-(2-hydroxy-4-oxo-6- phenethyl-6-propyl-5H-pyran-3-yl) propyl] phenyl] quinoline- 8-sulfonamide | |
Identifiers | |
CAS number | 174484-41-4 |
ATC code | J05AE09 |
PubChem | 65027 |
DrugBank | APRD01306 |
Chemical data | |
Formula | C31H33N2F3O5S |
Mol. weight | 584.726 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | 5-6 hours |
Excretion | ? |
Therapeutic considerations | |
Licence data | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) with the trade name Aptivus®. It is used in combination therapy to treat HIV infection.
Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors. Resistance to tipranavir itself seems to require multiple mutations.[1] Tipranavir is given in combination with ritonavir 200 mg twice daily.
Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005. Nelfinavir is the only other FDA approved nonpeptidic protease inhibitor. Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, it tends to have more side effects.
[edit] References
- ^ Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley M (2005). "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.". Antiviral Res 68 (1): 27-35. PMID 16122817. Retrieved on 2006-01-20.
Antivirals (primarily J05A, also S01AD and D06BB) edit | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|